Procyclidine

Summary

Procyclidine (CHEMBL86715) is an approved small-molecule muscarinic antagonist (ATC N04AA04); indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N04AA04
• Indications: 1 condition
• Chemistry: 287.4 Da · C19H29NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL86715
Name	Procyclidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4919
ChEBI	CHEBI:8448
ATC	N04AA04
Molecular formula	C19H29NO
Molecular weight	287.4
InChIKey	WYDUSKDSKCASEF-UHFFFAOYSA-N

SMILES: C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O

IUPAC name: 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol

ChEBI definition: A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.

Pharmacological roles (ChEBI): muscarinic antagonist, antiparkinson drug, antidyskinesia agent.

Also known as: Elorine, Kemadrine, Lergine, NSC-169103, Prociclidina, Procyclidine, Tricoloid, Vagosin, procyclidine, PROCYCLIDINE, PROCYCLIDINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1761

Patent coverage: 1,504 distinct patent families (5,456 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Glutamate [NMDA] receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Histamine H1 receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3, Histamine H1 receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM1	7.51	AC50	31	nM	CHEMBL_ACT_25210768
CHRM2	6.96	AC50	110	nM	CHEMBL_ACT_25196377
CHRM3	6.89	AC50	130	nM	CHEMBL_ACT_25136472
CHRM1	6.82	AC50	150	nM	CHEMBL_ACT_25135221
CHRM2	6.39	AC50	410.9	nM	CHEMBL_ACT_25195210
CHRM2	5.92	AC50	1200	nM	CHEMBL_ACT_25213524
GRIN2D	5.77	Ki	1700	nM	CHEMBL_ACT_834423
P31390	5.17	IC50	6761	nM	CHEMBL_ACT_12085959
KCNH2	5.12	AC50	7529	nM	CHEMBL_ACT_25117534

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	4	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).